Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
Antonio Cavazzuti
Giuseppe Paglietti
William N. Hunter
Francisco Gamarro
Sandra Piras
Mario Loriga
Sergio Alleca
Paola Corona
Karen McLuskey
Lindsay Tulloch
Federica Gibellini
Stefania Ferrari
Maria Paola Costin
Lindsay Tulloch
Tulloch Lindsay
ORCID: 0000-0001-7223-5106
Simplifying nature
10.1016/j.bmc.2017.01.021
Development of simplified heterocyclic acetogenin analogues as potent and selective Trypanosoma brucei inhibitors
10.1002/cmdc.201600210
Non-natural acetogenin analogues as potent Trypanosoma brucei inhibitors
10.1002/cmdc.201402272
A separate pool of cardiac phospholemman that does not regulate or associate with the sodium pump: multimers of phospholemman in ventricular muscle.
10.1074/jbc.m113.460956
Regulation of the cardiac Na(+) pump by palmitoylation of its catalytic and regulatory subunits.
10.1042/bst20120269
Regulation of the cardiac sodium pump.
10.1007/s00018-012-1134-y
The inhibitory effect of phospholemman on the sodium pump requires its palmitoylation.
10.1074/jbc.m111.282145
Robust neutralising activity and activation of neutrophil cytotoxic responses mediated by antibodies targeting the HTLV-1 envelope glycoprotein.
10.1186/1742-4690-8-s1-a170
Structure of recombinant Leishmania donovani pteridine reductase reveals a disordered active site.
10.1107/s174430911004724x
High-resolution structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target.
10.1107/s0907444910040886
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
10.1021/jm901059x
One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening
10.1021/jm900414x
Diversity oriented syntheses of fused pyrimidines designed as potential antifolates
10.1039/b818339b
Sulphate Removal Induces a Major Conformational Change in Leishmania mexicana Pyruvate Kinase in the Crystalline State
10.1016/j.jmb.2008.08.037
Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis
10.1016/j.bmc.2008.03.045
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
10.1073/pnas.0704384105
Structure of Staphylococcus aureus1,4-dihydroxy-2-naphthoyl-CoA synthase (MenB) in complex with acetoacetyl-CoA.
10.1107/s1744309107047720
Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate
10.1111/j.1365-2958.2006.05332.x
Direct and indirect approaches to identify drug modes of action.
10.1002/iub.1697
Design and synthesis of broad spectrum trypanosomatid selective inhibitors
10.1021/acsinfecdis.7b00187
Greasing the wheels or a spanner in the works? Regulation of the cardiac sodium pump by palmitoylation
10.1080/10409238.2018.1432560
Photo-affinity labelling and biochemical analyses identify the target of trypanocidal simplified natural product analogues
10.1371/journal.pntd.0005886
Structure‐based design, synthesis and biological evaluation of bis‐tetrahydropyran furan acetogenin mimics targeting the trypanosomatid F1 component of ATP synthase
10.1002/ejoc.201900541
Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series
10.3390/microorganisms9071408
Maria Paola Costi
Costi Maria Paola
ORCID: 0000-0002-0443-5402
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides
10.1021/jm5011176
Hotspots in an Obligate Homodimeric Anticancer Target. Structural and Functional Effects of Interfacial Mutations in Human Thymidylate Synthase
10.1021/acs.jmedchem.5b00137
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the thymidylate synthase reaction (vol 343, pg 1, 1995)
10.1016/j.comptc.2014.03.012
2- N-Alkyl(R-phenyl)-aminomethyl -3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes
10.1016/j.ejmech.2014.01.048
Internalization and Stability of a Thymidylate Synthase Peptide Inhibitor in Ovarian Cancer Cells
10.1021/jm501397h
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides
10.1021/pr500510v
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth
10.1021/jm401574p
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative
10.1021/jm5006572
2 '-Deoxyuridine 5 '-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho 1,8-bc furan-2-one Derivatives
10.1021/jm4014086
Biochemical effects of riluzole on Leishmania parasites
10.1016/j.exppara.2012.11.013
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity
10.1038/srep01035
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo de isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors
10.1016/j.bmcl.2012.11.117
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and-resistant human ovarian cancer cells
10.3892/ijo.2013.2045
Translational repression of thymidylate synthase by targeting its mRNA
10.1093/nar/gkt098
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines
10.1007/s10637-011-9733-2
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells
10.1007/s00726-011-1039-3
Inhibitor of Ovarian Cancer Cells Growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase
10.1021/jm300850v
Structure-Based Selectivity Optimization of Piperidine-Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors
10.1021/jm300563f
The structure of Enterococcus faecalis thymidylate synthase provides clues about folate bacterial metabolism
10.1107/s0907444912026236
Identification of the Binding Modes of N-Phenylphthalimides Inhibiting Bacterial Thymidylate Synthase through X-Ray Crystallography Screening
10.1021/jm2005018
Permeation through the cell membrane of a boron-based β-lactamase inhibitor
10.1371/journal.pone.0023187
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase
10.1073/pnas.1104829108
Virtual Screening Identification of Nonfolate Compounds, Including a CNS Drug, as Antiparasitic Agents Inhibiting Pteridine Reductase
10.1021/jm1010572
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding
10.1093/protein/gzp075
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer
10.1002/pro.379
Drug resistance in ovarian cancer: Biomarkers and treatments Highlights from the DROC meeting held in Modena (Italy) on the 19th and 20th of February 2009. Scientific topics discussed at the meeting are reported in the present issue
10.1016/j.ygyno.2010.03.006
Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors
10.1016/j.bmc.2010.09.065
Novel Approaches for Targeting Thymidylate Synthase To Overcome the Resistance and Toxicity of Anticancer Drugs
10.1021/jm901869w
Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines
10.1016/j.ygyno.2009.11.030
Structural study of phenyl boronic acid derivatives as AmpC β-lactamase inhibitors
10.1016/j.bmcl.2010.04.007
Anchors away
10.1038/458840a
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells
10.1016/j.ejphar.2009.04.062
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase
10.1021/jm701500e
Constrained dansyl derivatives reveal bacterial specificity of high conserved thymidylate synthases
10.1002/cbic.200700524
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
10.1073/pnas.0704384105
Opening opportunities for new drugs against neglected diseases
10.1002/cmdc.200800036
Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family
10.1002/cmdc.200700215
Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N- 4 (5,7-diamino-3-phenylquinoxalin-2-yl)amino benzoyl -L-glutamic acid diethyl ester: Evaluation of in vitro anti-cancer and anti-folate activities
10.1016/j.ejmech.2007.03.035
New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines
10.1016/j.tiv.2006.09.023
Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy
10.1021/jm070643q
Antibacterial agent discovery using thymidylate synthase biolibrary screening
10.1021/jm051187d
Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux
10.1128/aac.00423-06
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine
10.1021/jm0491445
The structure of Cryptococcus neoformans thymidylate synthase suggests strategies for using target dynamics for species-specific inhibition
10.1107/s0907444905022638
Thymidylate synthase structure, function and implication in drug discovery
10.2174/0929867054864868
Aza-boronic acids as non-β-lactam inhibitors of AmpC-β-lactamase
10.1016/j.bmcl.2004.05.054
Inhibitor specificity via protein dynamics: Insights from the design of antibacterial agents targeted against thymidylate synthase
10.1016/j.chembiol.2003.11.012
ortho-halogen naphthaleins as specific inhibitors of Lactobacillus casei thymidylate synthase. Conformational properties and biological activity
10.1016/s0968-0896(02)00541-2
The structural roles of conserved Pro196, Pro197 and His199 in the mechanism of thymidylate synthase
10.1093/protein/gzg076
Structure-based studies on species-specific inhibition of thymidylate synthase
10.1016/s0925-4439(02)00083-2
Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase
10.1016/s1074-5521(01)00067-9
Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase
10.1016/s1074-5521(01)00034-5
Update on antifolate drugs targets
10.2174/1389450013348669
Structures and reactivities of 1-oxo-cycloalkan-2-ylideneacetic acids. A H-1 NMR, modelling and photochemical study
10.1016/s0040-4020(00)00662-1
Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition
10.1021/jm9900016
Structure-based design of inhibitors specific for bacterial thymidylate synthase
10.1021/bi9815896
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase
10.1016/s1074-5521(99)80077-5
Quinoxaline chemistry. Part 11. 3-phenyl-2 phenoxy- and phenoxymethyl -6(7) or 6,8-substituted quinoxalines and N- 4-(6(7)-substituted or 6,8-disubstituted-3-phenylquinoxalin-2-yl)hydroxy or hydroxymethyl benzoylglutamates. Synthesis and evaluation of in vitro anticancer activity and enzymatic inhibitory activity against dihydrofolate reductase and thymidylate synthase
10.1016/s0014-827x(98)00054-8
Thymidylate synthase inhibition: A structure-based rationale for drug design (vol 18, pg 21, 1998)
10.1002/(sici)1098-1128(199805)18:3<187::aid-med3>3.0.co;2-t
Asparagine 229 mutants of thymidylate synthase catalyze the methylation of 3-methyl-2'-deoxyuridine 5'-monophosphate
10.1021/bi952642i
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations
10.1016/0968-0896(96)00193-9
Naphthalimido derivatives as antifolate thymidylate synthase inhibitors
10.1016/s0223-5234(97)86180-6
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics
10.1016/1010-6030(94)80047-2
THEORETICAL-STUDY OF ELECTRONIC-SPECTRA AND PHOTOPHYSICS OF URACIL DERIVATIVES
10.1111/j.1751-1097.1990.tb04192.x
Long period fiber grating biosensor for the detection of drug resistant bacteria: The 'OPTObacteria' project
10.1109/MePhoCo.2014.6866453
The inhibition of extended spectrum β-lactamases: Hits and leads
10.2174/09298673113206660323
Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase
10.1002/9783527670383.ch24
A primary pulmonary artery chondrosarcoma manifesting as acute pulmonary embolism
10.1016/j.athoracsur.2012.03.108
Homodimeric enzymes as drug targets
10.2174/092986710790712156
Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents
10.1002/jhet.5570430304
Structure-based optimization of a non-β-lactam lead results in inhibitors that do not up-regulate β-lactamase expression in cell culture
10.1021/ja042984o
Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]- benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]- benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities
10.1016/S0014-827X(02)00005-8
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the thymidylate synthase reaction
10.1016/0166-1280(95)90513-8
Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case
10.1002/cmdc.201600121
Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity
10.3390/molecules22030426
Repurposing of Drugs Targeting YAP-TEAD Functions
10.3390/cancers10090329
Structural Comparison of Enterococcus faecalis and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities
10.3390/molecules24071257
Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors
10.3390/molecules24071362
Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors
10.1021/acsinfecdis.8b00358
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth
10.3390/molecules24193493
The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines
10.3390/ijms20246122
Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology
10.1021/acs.jmedchem.9b01456
New Insights into Bioactive Compounds from the Medicinal Plant Spathodea campanulata P. Beauv. and Their Activity against Helicobacter pylori
10.3390/antibiotics9050258
High-resolution crystal structure of Trypanosoma brucei pteridine reductase 1 in complex with an innovative tricyclic-based inhibitor
10.1107/S2059798320004891
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells
10.3390/ijms21124452
Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations
10.3390/cancers13092061
Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase
10.3390/ph14070636
Design, Synthesis and Antiparasitic Evaluation of Click Phospholipids
10.3390/molecules26144204
Francisco Gamarro
Gamarro Francisco
ORCID: 0000-0003-1347-3440
Functional role of highly conserved residues of the N-terminal tail and first transmembrane segment of a P4-ATPase.
10.1042/bcj20170749
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
10.1371/journal.pntd.0006052
Leishmania LABCG2 transporter is involved in ATP-dependent transport of thiols.
10.1042/bcj20170685
ABCI3 Is a New Mitochondrial ABC Transporter from Leishmania major Involved in Susceptibility to Antimonials and Infectivity.
10.1128/aac.01115-17
Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.
10.1016/j.bmcl.2017.07.032
Leishmania LABCG1 and LABCG2 transporters are involved in virulence and oxidative stress: functional linkage with autophagy.
10.1186/s13071-017-2198-1
Arylthiosemicarbazones as antileishmanial agents.
10.1016/j.ejmech.2016.07.014
Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
10.1016/j.ijpddr.2016.04.003
Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
10.1371/journal.pone.0154101
Tyrosol and hydroxytyrosol derivatives as antitrypanosomal and antileishmanial agents.
10.1016/j.ejmech.2016.04.047
The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.
10.1128/aac.02813-15
Optimization by Molecular Fine Tuning of Dihydro-β-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance.
10.1021/acs.jmedchem.5b01429
The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei.
10.1128/aac.00879-15
Fitness of Leishmania donovani parasites resistant to drug combinations.
10.1371/journal.pntd.0003704
Restoration of Chemosensitivity in P-Glycoprotein-Dependent Multidrug-Resistant Cells by Dihydro-β-agarofuran Sesquiterpenes from Celastrus vulcanicola.
10.1021/np500903a
Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.
10.1128/aac.04231-14
Mechanisms of action of substituted β-amino alkanols on Leishmania donovani.
10.1128/aac.04003-14
High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
10.1177/1087057114555846
Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes.
10.1016/j.ejmech.2014.10.040
4-amino bis-pyridinium derivatives as novel antileishmanial agents.
10.1128/aac.02481-13
Functional role of evolutionarily highly conserved residues, N-glycosylation level and domains of the Leishmania miltefosine transporter-Cdc50 subunit.
10.1042/bj20131318
Identification of specific reversal agents for Leishmania ABCI4-mediated antimony resistance by flavonoid and trolox derivative screening.
10.1093/jac/dkt407
A new ABC half-transporter in Leishmania major is involved in resistance to antimony.
10.1128/aac.00211-13
LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania.
10.1371/journal.pntd.0002179
Leishmania donovani develops resistance to drug combinations.
10.1371/journal.pntd.0001974
Oxazolo[3,2-a]pyridine. A new structural scaffold for the reversal of multi-drug resistance in Leishmania.
10.1016/j.bmcl.2012.07.100
Terpenoids from Maytenus species and assessment of their reversal activity against a multidrug-resistant Leishmania tropica line.
10.1002/cbdv.201000356
Uptake of the antileishmania drug tafenoquine follows a sterol-dependent diffusion process in Leishmania.
10.1093/jac/dkr345
Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes.
10.1016/j.ejmech.2011.07.048
The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase.
10.1128/aac.00520-11
Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.
10.1128/aac.00065-11
A new ATP-binding cassette protein is involved in intracellular haem trafficking in Leishmania.
10.1111/j.1365-2958.2010.07531.x
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
10.1128/aac.01545-10
Antileishmanial and Antitrypanosomal Activities of the 8-Aminoquinoline Tafenoquine.
10.1128/aac.01592-10
Non-reducing trisaccharide fatty acid monoesters: novel detergents in membrane biochemistry.
10.1016/j.bbamem.2010.11.031
Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis.
10.1128/aac.00790-10
Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.
10.1128/aac.00985-10
Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion.
10.1371/journal.pone.0012443
Leishmanicidal and reversal multidrug resistance constituents from Aeonium lindleyi.
10.1055/s-0030-1250144
CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cells.
10.1016/j.bcp.2010.05.017
Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance.
10.1039/b915678j
Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.
10.1128/aac.01694-08
Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.
10.1021/jm800403b
Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes.
10.1128/aac.00964-08
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
10.1128/aac.00587-08
All in one: Leishmania major STT3 proteins substitute for the whole oligosaccharyltransferase complex in Saccharomyces cerevisiae.
10.1091/mbc.e08-05-0467
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development.
10.1073/pnas.0704384105
New terpenoids from Maytenus apurimacensis as MDR reversal agents in the parasite Leishmania.
10.1016/j.bmc.2007.10.071
The anti-tumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cells.
10.1016/j.bbamem.2007.10.017
Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance.
10.1021/jm070290v
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
10.1016/j.ijantimicag.2007.05.007
A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids.
10.1111/j.1365-2958.2007.05653.x
Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.
10.1128/aac.00423-06
Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.
10.1074/jbc.m605214200
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
10.1016/j.drup.2006.04.001
Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific, non-transported inhibitors of human P-glycoprotein.
10.1016/j.bbamem.2005.12.006
Reversion of human Pgp-dependent multidrug resistance by new sesquiterpenes from Zinowiewia costaricensis.
10.1021/jm058003f
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
10.1158/0008-5472.can-04-1817
The overexpression of an intracellular ABCA-like transporter alters phospholipid trafficking in Leishmania.
10.1016/j.bbrc.2005.02.176
Functional expression of a multidrug P-glycoprotein transporter of Leishmania.
10.1016/j.bbrc.2005.02.009
Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania.
10.2174/1381612054864920
Characterization of an ABCA-like transporter involved in vesicular trafficking in the protozoan parasite Trypanosoma cruzi.
10.1111/j.1365-2958.2004.04304.x
Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
10.1158/0008-5472.can-04-1005
SAR studies of dihydro-beta-agarofuran sesquiterpenes as inhibitors of the multidrug-resistance phenotype in a Leishmania tropica line overexpressing a P-glycoprotein-like transporter.
10.1021/jm0309699
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
10.1016/s0924-8579(03)00125-0
Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
10.1074/jbc.m308352200
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.
10.1128/aac.47.8.2397-2403.2003
The overexpression of a new ABC transporter in Leishmania is related to phospholipid trafficking and reduced infectivity.
10.1016/s0005-2736(03)00131-7
Rapid transport of phospholipids across the plasma membrane of Leishmania infantum.
10.1016/s0006-291x(03)00947-1
RU49953: a non-hormonal steroid derivative that potently inhibits P-glycoprotein and reverts cellular multidrug resistance.
10.1007/s000180300044
Two casein kinase 1 isoforms are differentially expressed in Trypanosoma cruzi.
10.1016/s0166-6851(02)00156-1
Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents.
10.2174/1389450023347588
Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters.
10.1007/s00018-002-8424-8
Chemosensitization of a multidrug-resistant Leishmania tropica line by new sesquiterpenes from Maytenus magellanica and Maytenus chubutensis.
10.1021/jm010970c
ABC transporters in the protozoan parasite Leishmania.
10.1007/s10123-001-0031-2
Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator.
10.1128/aac.45.9.2468-2474.2001
Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity.
10.1021/bi002453m
High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin.
10.1128/aac.45.2.439-446.2001
Evolutionary relationships in Trypanosoma cruzi: molecular phylogenetics supports the existence of a new major lineage of strains.
10.1016/s0378-1119(00)00074-3
Trypanosoma cruzi: molecular cloning of a gene coding for a putative vacuolar protein.
10.1006/expr.1999.4485
Characterization of a new ATP-binding cassette transporter in Trypanosoma cruzi associated to a L1Tc retrotransposon.
10.1016/s0167-4781(99)00195-5
New natural sesquiterpenes as modulators of daunomycin resistance in a multidrug-resistant Leishmania tropica line.
10.1021/jm991066b
Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin.
10.1021/bi982455v
Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica.
10.1016/s0006-2952(98)00129-4
A new member of YER057c family in Trypanosoma cruzi is adjacent to an ABC-transporter.
10.1016/s0378-1119(98)00439-9
Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line.
10.1016/s0006-2952(97)00385-7
A pteridine reductase gene ptr1 contiguous to a P-glycoprotein confers resistance to antifolates in Trypanosoma cruzi.
10.1016/s0166-6851(97)00207-7
An amino acid channel activated by hypotonically induced swelling of Leishmania major promastigotes.
10.1042/bj3190691
Molecular characterization of a P-glycoprotein-related tcpgp2 gene in Trypanosoma cruzi.
10.1016/0166-6851(95)02519-7
Addendum to "Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: gene isolation and expression and characterization of the enzyme" [Mol. Biochem. Parasitol. 72 (1995) 11-22].
10.1016/0166-6851(95)02532-4
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: gene isolation and expression and characterization of the enzyme.
10.1016/0166-6851(95)00059-a
Trypanosoma cruzi: sequence of the ATP-binding site of a P-glycoprotein gene.
10.1006/expr.1994.1061
P-glycoprotein overexpression in methotrexate-resistant Leishmania tropica.
10.1016/0006-2952(94)90067-1
The different behavior of diphtheria toxin, modeccin and ricin in HeLa cells infected with Trypanosoma cruzi.
10.1111/j.1550-7408.1994.tb01503.x
Increased P-type ATPase activity in Leishmania tropica resistant to methotrexate.
10.1006/bbrc.1994.1307
Possible coexistence of two independent mechanisms contributing to anthracycline resistance in leukaemia P388 cells.
10.1016/0959-8049(93)90050-p
Trypanosoma cruzi: calcium ion movement during internalization in host HeLa cells.
10.1016/0020-7519(90)90126-8
Purification of a glycoprotein excreted by Trypanosoma cruzi to increase the permeability of the host-cell membrane.
10.1016/0006-291x(90)90871-j
New antiparasitic agents. III. Comparison between trypanocidal activities of some acridine derivatives against Trypanosoma cruzi in vitro.
10.1159/000238559
Antiamebic activity of new acridinic derivatives against Naegleria and Acanthamoeba species in vitro.
10.1159/000238471
Inhibition of lysosomal fusion by Trypanosoma cruzi in peritoneal macrophages.
10.1016/0020-7519(86)90031-7
Effect of interferon on the infectivity of Trypanosoma cruzi in cultured HeLa cells.
10.1016/0020-7519(85)90082-7
[Effect of proteolytic enzymes on the penetration of Trypanosoma cruzi in peritoneal macrophages of mice].
10.1051/parasite/1985604383
Effect of poly-L-lysine and neuraminidase on the infectivity of Trypanosoma cruzi in cultured HeLa cells.
10.1007/bf00928345
Isolation and purification of amastigotes of Trypanosoma cruzi from cultured vero cells.
10.1007/bf00932914
Some factors affecting the in vitro invasion of HeLa cells by Trypanosoma cruzi.
10.1016/0020-7519(84)90076-6
Purification of metacyclic forms of Trypanosoma cruzi by Percoll discontinuous gradient centrifugation.
10.1007/bf00926684
Karen McLuskey
McLuskey Karen
ORCID: 0000-0002-9841-4943
PNT1 Is a C11 Cysteine Peptidase Essential for Replication of the Trypanosome Kinetoplast
10.1074/jbc.M116.714972
Crystal Structure and Activity Studies of the C11 Cysteine Peptidase from Parabacteroides merdae in the Human Gut Microbiome
10.1074/jbc.M115.706143
Crystal structures of all-alpha type membrane proteins.
10.1007/s00249-009-0546-6
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development.
10.1073/pnas.0704384105
Crystallization and preliminary x-ray crystallographic analysis of the B800-820 light-harvesting complex from Rhodopseudomonas acidophila strain 7050.
10.1107/s0907444998016059
Comparative structural analysis of the caspase family with other clan CD cysteine peptidases.
10.1042/bj20141324
Purification, characterization, and crystallization of Trypanosoma metacaspases.
10.1007/978-1-4939-0357-3_13
Substrate specificity and the effect of calcium on Trypanosoma brucei metacaspase 2.
10.1111/febs.12248
Crystal structure of a Trypanosoma brucei metacaspase.
10.1073/pnas.1200885109
Oligopeptidase B deficient mutants of Leishmania major.
10.1016/j.molbiopara.2010.09.003
The crystal structure of the periplasmic domain of the type II secretion system protein EpsM from Vibrio cholerae: the simplest version of the ferredoxin fold.
10.1016/j.jmb.2004.01.064
Crystal structure of Leishmania major oligopeptidase B gives insight into the enzymatic properties of a trypanosomatid virulence factor.
10.1074/jbc.m110.156679
Initiating a crystallographic analysis of recombinant (S)-2-hydroxypropylphosphonic acid epoxidase from Streptomyces wedmorensis.
10.1107/s1744309105012376
Insight into the role of Escherichia coli MobB in molybdenum cofactor biosynthesis based on the high resolution crystal structure.
10.1074/jbc.m301485200
Structure and reactivity of hydroxypropylphosphonic acid epoxidase in fosfomycin biosynthesis by a cation- and flavin-dependent mechanism.
10.1073/pnas.0504314102
A protocol for high throughput methods for the expression and purification of inner membrane proteins.
10.1080/09687680802510289
High-throughput identification of purification conditions leads to preliminary crystallization conditions for three inner membrane proteins.
10.3109/09687688.2011.628954
High-throughput methods for the detection of protein overexpression using fluorescence markers.
10.1016/b978-0-12-407239-8.00010-0
Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate.
10.1111/j.1365-2958.2006.05332.x
How purple photosynthetic bacteria harvest solar energy
10.1016/j.crci.2005.03.035
Structural factors which control the position of the Qy absorption band of bacteriochlorophyll a in purple bacterial antenna complexes
10.1023/a:1020995224156
Inhibition ofLeishmania majorpteridine reductase by 2,4,6-triaminoquinazoline: structure of the NADPH ternary complex
10.1107/s0907444904018955
Ranking Metabolite Sets by Their Activity Levels
10.3390/metabo11020103
The crystallographic structure of the B800-820 LH3 light-harvesting complex from the purple bacteria Rhodopseudomonas acidophila strain 7050.
10.1021/bi010309a
Stefania Ferrari
Ferrari Stefania
ORCID: 0000-0003-1149-5953
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells
10.1021/jm501397h
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes
10.1016/j.ejmech.2014.01.048
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth
10.1021/jm401574p
2′-deoxyuridine 5′-monophosphate substrate displacement in thymidylate synthase through 6-Hydroxy-2 H -naphtho[1,8- bc ]furan-2-one derivatives
10.1021/jm4014086
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and-resistant human ovarian cancer cells
10.3892/ijo.2013.2045
Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase
10.1002/9783527670383.ch24
Biochemical effects of riluzole on Leishmania parasites
10.1016/j.exppara.2012.11.013
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)- carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors
10.1016/j.bmcl.2012.11.117
Inhibitor of ovarian cancer cells growth by virtual screening: A new thiazole derivative targeting human thymidylate synthase
10.1021/jm300850v
Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors
10.1021/jm300563f
The structure of Enterococcus faecalis thymidylate synthase provides clues about folate bacterial metabolism
10.1107/S0907444912026236
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase (Proceedings of the National Academy of Sciences of the United States of America (2011) 108, 34 (E542-E549) DOI: 10.1073/pnas.1104829108)
10.1073/pnas.1113637108
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase
10.1073/pnas.1104829108
Identification of the binding modes of N-phenylphthalimides inhibiting bacterial thymidylate synthase through X-ray crystallography screening
10.1021/jm2005018
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase
10.1021/jm1010572
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer
10.1002/pro.379
Homodimeric enzymes as drug targets
10.2174/092986710790712156
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding
10.1093/protein/gzp075
Anchors away
10.1038/458840a
Constrained dansyl derivatives reveal bacterial specificity of high conserved thymidylate synthases
10.1002/cbic.200700524
Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family
10.1002/cmdc.200700215
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development
10.1073/pnas.0704384105
Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: Evaluation of in vitro anti-cancer and anti-folate activities
10.1016/j.ejmech.2007.03.035
Antibacterial agent discovery using thymidylate synthase biolibrary screening
10.1021/jm051187d
Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents
10.1002/jhet.5570430304
The structure of Cryptococcus neoformans thymidylate synthase suggests strategies for using target dynamics for species-specific inhibition
10.1107/S0907444905022638
Thymidylate synthase structure, function and implication in drug discovery
10.2174/0929867054864868
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine
10.1021/jm0491445
Aza-boronic acids as non-β-lactam inhibitors of AmpC-β-lactamase
10.1016/j.bmcl.2004.05.054
Inhibitor Specificity via Protein Dynamics: Insights from the Design of Antibacterial Agents Targeted Against Thymidylate Synthase
10.1016/j.chembiol.2003.11.012
Update on antifolate drugs targets
10.2174/1389450013348669
Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase
10.1021/acs.jmedchem.5b00137
Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case
10.1002/cmdc.201600121
X-ray crystal structures of Enterococcus faecalis thymidylate synthase with folate binding site inhibitors
10.1016/j.ejmech.2016.07.066
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance
10.1016/j.drup.2015.10.003
2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1
10.1021/cb5007163
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment
10.1021/jm501615v
Protein-protein interaction inhibitors: Case studies on small molecules and natural compounds
10.1007/978-3-642-37999-4_2
Profiling of flavonol derivatives for the development of antitrypanosomatidic drugs
10.1021/acs.jmedchem.6b00698
Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity
10.3390/molecules22030426
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth
10.1021/acs.jmedchem.7b01699
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent
10.1021/acsmedchemlett.8b00565
Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors
10.3390/molecules24071362
